MedTrace Logo

Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

NCT07095465 · Status: ENROLLING_BY_INVITATION · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2026-04-22

No results posted yet for this study

Summary

A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

Conditions

  • Lewy Body Dementia Psychosis

Interventions

DRUG

ACP-204

Provided as 1 capsule, to be taken orally once daily

Sponsors & Collaborators

  • ACADIA Pharmaceuticals Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-14
Primary Completion
2029-02-28
Completion
2029-03-31
FDA Drug
Yes

Countries

  • United States
  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07095465 on ClinicalTrials.gov